AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Incanthera plc

Investor Presentation Oct 16, 2025

10290_rns_2025-10-16_7c1d5a7e-3b3a-48c1-929f-4ad65c9f076b.html

Investor Presentation

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 6763D

Incanthera PLC

16 October 2025

Goal Group

16 October 2025

Incanthera plc

("Incanthera" the "Company")

Investor Presentation

Proactive Investor Forum Presentation

Incanthera plc   (AQSE:INC), the   company specially focussed on innovative technologies in dermatology and oncology, advises that following their presentation at Proactive investor's One2One Biotech Investor Forum in London on 9 October 2025, the recording of the company's presentation is now available on the following link:

https://www.youtube.com/embed/mMnfpaj1ZCE?si=pikzFDks4YpOQ_En

This is also available to view on the Company's website, along with the investor presentation, given on the evening, at https://www.incanthera.com/investors/results-reports-and-presentations/ .

RNS Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.

For further enquiries:

Incanthera plc:                                                                                                                                                                 

www.incanthera.com

Tim McCarthy, Chairman

[email protected]

Simon Ward, Chief Executive Officer

[email protected]

Suzanne Brocks, Head of Communications [email protected]
+44 (0) 7831 675747

+44 (0) 7747 625506

+44 (0) 7776 234600
Broker: 

Stanford Capital Partners Ltd

Patrick Claridge / Bob Pountney
+44 (0) 20 3650 3650/51

Notes to Editors

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford.  Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit:  www.incanthera.com

@incantheraplc

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUNRKRVBURARA

Talk to a Data Expert

Have a question? We'll get back to you promptly.